CURRICULUM VITAE PERSONAL: Name: Address: Telephone: FAX: Email: EDUCATION: Post-Doctoral Biology Ph.D. B.S. (honors) David Jay Segal Genome Center Department of Biochemistry and Molecular Medicine University of California, Davis 4512 GBSF 451 Health Sciences Dr. Davis, CA 95616 530-754-9134 530-754-9658 [email protected] 2002 The Scripps Research Inst, La Jolla, CA Molecular 1996 1989 University of Utah, Salt Lake City, UT Biochemistry Cornell University, Ithaca, NY Biology PROFESSIONAL EXPERIENCE: 2014-present Professor, Genome Center, Biochemistry and Molecular Medicine, Pharmacology, and the M.I.N.D. Institute, University of California, Davis, CA. 2013-2014 Associate Professor, M.I.N.D. Institute, University of California, Davis, CA. 2013-present Adjunct Without Salary, Texas A&M University, TX. 2011-2015 Associate Director of Genomics for the UC Davis Genome Center. 2010-2014 Associate Professor, Dept. of Biochemistry and Molecular Medicine, School of Medicine. University of California, Davis, CA. 2008-2010 Associate Professor, Genome Center and Dept. of Pharmacology, School of Medicine. University of California, Davis, CA. 2005-2008 Assistant Professor, Genome Center and Dept. of Pharmacology, School of Medicine. University of California, Davis, CA. 2002-2005 Assistant Professor, Dept. of Pharmacology and Toxicology, College of Pharmacy. University of Arizona, Tucson, AZ. CURRENT RESEARCH ACTIVITIES: The Segal Lab is developing gene and epigenome editing approaches for therapy, including: • Tools: Zinc finger, TALE, and CRISPR/Cas programmable platforms for targeted nucleases, epigenetic modifiers, transposases, transcription factors. • CRISPR, CRISPRa, CRISPRi screens to discover therapeutic target genes • Delivery: Protein, viral, and cell systems for delivery of editing tools into the brain in vivo • Molecular Therapy: For neurologic genetic disorders such as Angelman Syndrome 1 Segal, D.J. Curriculum Vita 2 RESEARCH SUPPORT: Active: Grant (Silverman) 05/01/21 – 04/30/24 0.24 cal months SYNGAP Foundation $ 396,435 ADC “Center for Interventional Genetics Program on SYNGAP1” The major goal is to develop a molecular therapy for SYNGAP1 deficiency. Role: Co-I Grant (Segal, Silverman) 02/01/20 - 01/31/25 1.2 cal months Found. Angelman Syndrome Therapeutics $372,811 ADC “FAST Research Infrastructure Grant” The goal of this project is to evaluate drug and molecular therapies for Angelman syndrome. UH2 EB028910 (Tarantal, Segal) 07/01/19 – 06/30/23 0.96 cal months NIH-NCATS $225,000 ADC “Innovative Translational Imaging Technologies to Non-Invasively Monitor Genome Edited Cells In Vivo” The major goal of this project is to develop PET imaging for tracking gene edited cells in vivo. UG3 TR002667 (Lam, Cheng) 07/01/19 – 06/30/23 0.6 cal months NIH-NCATS $ 750,600 ADC “Cell-specific nanocarrier with endocytic and endosomolytic activities for therapeutic genome editing” The major goal of this project is to develop novel nanoplatforms for efficient in vivo delivery of genome editing machinery into specific cell types. Role: Co-I U42 OD027094 (Tarantal, Segal) 04/15/19 – 03/31/24 1.8 cal months NIH-Common Fund $ 1,140,000 ADC “Nonhuman Primate Testing Center for Evaluation of Somatic Cell Genome Editing Tools” The major goal of this core is to test new gene editing technologies in non-human primates for the NIH Somatic Cell Gene Editing consortium. R21 HG010559 (Segal) 04/01/19 – 09/31/21 0.24 cal months NIH-NHGRI $142,426 ADC “Determinants of Persistence in Epigenetic Editing” The major goal of this project is to use screening methods to identify cellular factors that contribute to the persistence of epigenetic gene repression. Segal, D.J. Curriculum Vita 3 2019-67013-29012 (Brady, Patron, Segal) 12/15/18 – 12/31/21 1.2 cal months USDA-NIFA $70,000 ADC “BTT EAGER Engineering complex traits using targeted, multiplexed genetic and epigenetic mutagenesis” The major goal of this project is the genetic and epigenetic engineering of complex traits in plants. R21 NS104675 (Tarantal, Segal) 05/01/18 – 06/30/21 0.24 cal months NIH-NINDS $137,500 ADC “Precision Nonhuman Primate Models for Congenital Diseases” The major goal of this project is to use a new approach to develop new preclinical models of human disease using gene editing. FAST-Trak (Segal, Silverman) 01/01/20 – 06/30/21 0.36 cal months Found. Angelman Syndrome Therapeutics $ 135,000 ADC “Rodent Studies of Non-Snord116 Paternal Ube3a activation” The

docxDoc SEGAL_CV_21

Practical Docs > Common > Other > Preview
43 Pages 0 Downloads 12 Views 3.0 Score
Tips: Current document can only be previewed at most page3,If the total number of pages in the document exceeds page 3,please download the document。
Uploaded by admin on 2022-04-24 01:37:23
Rate
You can enter 255 characters
What is my domain?( answer:www.45doc.com )
comments
  • No comments yet